Providing Answers, Support and Hope in Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
New Investigational Oral Therapy, Afimetoran, for Systemic Lupus Erythematosus Meets Phase 2 Trial Endpoint
A new investigative therapy, afimetoran, for adults with systemic lupus erythematosus (SLE) met its primary endpoint in a Phase 2 global, double-blind, randomized, dose-ranging, placebo-controlled trial (NCT04895696), showing a clear, statistically significant, and clinically meaningful benefit. Afimetoran is a selective, oral, once-daily equipotent small-molecule inhibitor of Toll-like receptors 7 and 8 (TLR7/8). The drug has also been investigated in a Phase 1b trial for cutaneous lupus erythematosus (CLE), demonstrating exploratory efficacy and received Fast Track designation by the U.S. Food and Drug Administration for SLE in May 2025.
The Phase 2 trial enrolled 248 adults aged 18-70 years with active moderate-to-severe SLE receiving ongoing background treatment. Participants were randomized 1:1:1:1 to receive once-daily oral afimetoran at 1 of 3 dose levels or placebo through Week 48, in addition to protocol-permitted background standard of care medications, including corticosteroids with a mandatory corticosteroid taper. After 48 weeks of daily oral treatment, trial participants saw higher response rates across the three dose groups as measured by the SLE Responder Index-4 (SRI-4) versus those on placebo. The therapy’s secondary endpoints, which assessed measures such as low disease activity, skin and joint manifestations, corticosteroid reduction, physician global assessment, and quality of life, showed improvements consistent with the primary endpoint findings. Overall, the drug was generally well tolerated, with a safety profile consistent with previous Phase 1 clinical trial experience and no new safety signals observed. TLR7 and TLR8 play complimentary roles in lupus. Genetic studies have directly linked TLR7 to driving the disease, while TLR8 contributes by triggering the release of inflammatory molecules — a process that, over time, can worsen disease activity and lead to lasting organ damage.
Based on these positive results, Beeline Medicines plans to advance afimetoran into pivotal development for SLE and CLE. Detailed Phase 2 results are expected to be presented at an upcoming medical congress.
Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about medications used to treat lupus.